- Home
- SGMT vs NUW Comparison
SGMT vs NUW Comparison
Compare SGMT & NUW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGMT
- NUW
- Stock Information
- Founded
- SGMT 2006
- NUW 2008
- Country
- SGMT United States
- NUW United States
- Employees
- SGMT N/A
- NUW N/A
- Industry
- SGMT
- NUW Investment Managers
- Sector
- SGMT
- NUW Finance
- Exchange
- SGMT Nasdaq
- NUW Nasdaq
- Market Cap
- SGMT 238.7M
- NUW 252.2M
- IPO Year
- SGMT 2023
- NUW N/A
- Fundamental
- Price
- SGMT $7.31
- NUW N/A
- Analyst Decision
- SGMT Strong Buy
- NUW
- Analyst Count
- SGMT 7
- NUW 0
- Target Price
- SGMT $26.57
- NUW N/A
- AVG Volume (30 Days)
- SGMT 480.3K
- NUW 45.3K
- Earning Date
- SGMT 11-12-2025
- NUW 01-01-0001
- Dividend Yield
- SGMT N/A
- NUW 3.66%
- EPS Growth
- SGMT N/A
- NUW N/A
- EPS
- SGMT N/A
- NUW N/A
- Revenue
- SGMT N/A
- NUW N/A
- Revenue This Year
- SGMT N/A
- NUW N/A
- Revenue Next Year
- SGMT N/A
- NUW N/A
- P/E Ratio
- SGMT N/A
- NUW N/A
- Revenue Growth
- SGMT N/A
- NUW N/A
- 52 Week Low
- SGMT $1.73
- NUW $12.45
- 52 Week High
- SGMT $11.41
- NUW $14.44
- Technical
- Relative Strength Index (RSI)
- SGMT 52.06
- NUW 68.77
- Support Level
- SGMT $7.11
- NUW $13.97
- Resistance Level
- SGMT $7.66
- NUW $14.25
- Average True Range (ATR)
- SGMT 0.40
- NUW 0.10
- MACD
- SGMT 0.11
- NUW 0.01
- Stochastic Oscillator
- SGMT 76.45
- NUW 84.44
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.
About NUW Nuveen AMT-Free Municipal Value Fund
Nuveen AMT-Free Municipal Value Fund is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax by investing in a portfolio of municipal obligations. The fund predominantly invests in long-term municipal bonds, corporate bonds, short-term municipal bonds, and other assets.